Apr. 13 at 7:15 PM
$BNGO 2026 Outlook: 🚀
Financials: Targeting
$30M–
$33M revenue; heavy focus on debt clearance by May ‘26 to stabilize the balance sheet. 📉
Tech: Optical Genome Mapping (OGM) remains the "gold standard" for structural variants, outpacing competitors in cost-efficiency. 🧬
Catalyst: Higher US reimbursement rates for blood cancer tests (+
$1.X,853) driving clinical adoption. 🏥
Risk: Still a high-volatility play with delisting/dilution risks. ⚖️
Verdict: A high-stakes bet on OGM becoming the diagnostic norm. #Genomics #BioTech #Investing #BNGO